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Adropin: An endocrine link between the
biological clock and cholesterol homeostasis
Sarbani Ghoshal 1, Joseph R. Stevens 1, Cyrielle Billon 1, Clemence Girardet 1, Sadichha Sitaula 1,
Arthur S. Leon 2, D.C. Rao 3, James S. Skinner 4, Tuomo Rankinen 5, Claude Bouchard 5, Marinelle V. Nuñez 6,7,
Kimber L. Stanhope 6,7, Deborah A. Howatt 8, Alan Daugherty 8, Jinsong Zhang 1, Matthew Schuelke 1,
Edward P. Weiss 9, Alisha R. Coffey 10, Brian J. Bennett 11, Praveen Sethupathy 12, Thomas P. Burris 1,
Peter J. Havel 6,7, Andrew A. Butler 1,*
ABSTRACT
Objective: Identify determinants of plasma adropin concentrations, a secreted peptide translated from the Energy Homeostasis Associated
(ENHO) gene linked to metabolic control and vascular function.
Methods: Associations between plasma adropin concentrations, demographics (sex, age, BMI) and circulating biomarkers of lipid and glucose
metabolism were assessed in plasma obtained after an overnight fast in humans. The regulation of adropin expression was then assessed in
silico, in cultured human cells, and in animal models.
Results: In humans, plasma adropin concentrations are inversely related to atherogenic LDL-cholesterol (LDL-C) levels in men (n¼ 349), but not
in women (n ¼ 401). Analysis of hepatic Enho expression in male mice suggests control by the biological clock. Expression is rhythmic, peaking
during maximal food consumption in the dark correlating with transcriptional activation by RORa/g. The nadir in the light phase coincides with the
rest phase and repression by Rev-erb. Plasma adropin concentrations in nonhuman primates (rhesus monkeys) also exhibit peaks coinciding with
feeding times (07:00 h, 15:00 h). The ROR inverse agonists SR1001 and the 7-oxygenated sterols 7-b-hydroxysterol and 7-ketocholesterol, or the
Rev-erb agonist SR9009, suppress ENHO expression in cultured human HepG2 cells. Consumption of high-cholesterol diets suppress expression
of the adropin transcript in mouse liver. However, adropin over expression does not prevent hypercholesterolemia resulting from a high
cholesterol diet and/or LDL receptor mutations.
Conclusions: In humans, associations between plasma adropin concentrations and LDL-C suggest a link with hepatic lipid metabolism. Mouse
studies suggest that the relationship between adropin and cholesterol metabolism is unidirectional, and predominantly involves suppression of
adropin expression by cholesterol and 7-oxygenated sterols. Sensing of fatty acids, cholesterol and oxysterols by the RORa/g ligand-binding
domain suggests a plausible functional link between adropin expression and cellular lipid metabolism. Furthermore, the nuclear receptors
RORa/g and Rev-erb may couple adropin synthesis with circadian rhythms in carbohydrate and lipid metabolism.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords Cholesterol; LDL; Cardiovascular disease; Obesity; Adropin; Sex
1. INTRODUCTION
Secreted peptides are involved in signaling metabolic status at the
organismal and cellular levels to maintain cardiovascular and meta-
bolic homeostasis. Studies in male C57BL/6J (B6) mice suggest the
secreted peptide adropin provides such a signal of metabolic condition
[1]. Adropin is a product of the Energy Homeostasis Association (ENHO)
gene, comprised of two-exons on human chromosome 9p13.3. A
highly conserved open reading frame in exon 2 encodes the full-length
peptide (adropin176). Adropin133 is a secretory signal peptide [1];
adropin3476 is biologically active when administered to mice and
cultured cells. For example, adropin3476 alters whole body glucose
and lipid metabolism when administered to mice [1,2], rats [3,4], and
also activates signaling pathways in mammalian cell lines [5].
Adropin3476 may also function to preserve the circulatory system,
regulating endothelial function and activity of endothelial nitric oxide
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synthase [5e8]. The Enho transcript is however widely expressed,
with high levels of expression in the nervous system relative to other
tissues in B6 mice [1,5,9]. Analysis of male B6 mice that are adropin-
deﬁcient, over express adropin or are administered pharmacological
doses of synthetic peptide suggest adropin suppresses fat oxidation
and enhances oxidative glucose disposal and glucose tolerance
[1,2,10].
Studies investigating plasma adropin concentrations in humans and
nonhuman primates have observed associations with diet [11e14],
with indices of insulin resistance [6,11,15,16], and with risk for car-
diovascular disease [17,18]. However, determinants of plasma adropin
concentration in humans are still poorly deﬁned.
Here we report that plasma adropin concentrations are inversely
related to plasma levels of low-density lipoprotein cholesterol (LDL-C)
in males, but not in females. We also report that the biological clock
may be plausible focal point linking Enho transcription with nutrient
intake and cellular metabolic condition.
2. MATERIALS AND METHODS
2.1. Human studies
Plasma adropin concentrations were measured in the EDTA plasma
fraction of blood samples collected after an overnight fast in ﬁve
studies:
 389 participants of a previously unpublished and unregistered
Reference Range Study (RRS);
 Two NIH funded studies examining the impact of sugar consumption
over 2 wk (n ¼ 182) (DRS, NCT01103921) [19] or 10 wk (n ¼ 31)
(IPOP, NCT01165853) [20] on cardiometabolic risk factors;
 A randomized intervention trial examining weight loss on car-
diometabolic risk factors (Caloric Restriction, Exercise, and Glucor-
egulation in Humans; NCT00777621) (n ¼ 68) [21]; and
 Samples from participants of the HERITAGE study (NCT00005137)
examining the interactions between genetics and exercise on car-
diometabolic risk factors (n ¼ 80) [22].
The relationship between plasma adropin concentrations and athero-
genic cholesterol was assessed in data pooled from the RRS, DRS,
IPOP, CREG and HERITAGE studies [11,12,15]. These data sets were
selected based on collection of common demographic and blood
chemistry data (supplemental data, Table S1). The studies are cross
sectional, using plasma samples collected at baseline prior to dietary
and/or behavioral interventions, and incorporated previously published
data from smaller studies [11,12,15].
2.1.1. Reference range study
The original study involved 395 participants (190 men, 205 women)
aged 21e75y recruited by investigators at the University of California,
Davis, CA. EDTA-plasma samples were available from 187 male and
202 female volunteers for a study designed to validate a commercial
assay for small diameter LPL. Study participants were recruited
through an Internet listing (craigslist.com) and local postings of ﬂyer.
Subjects aged <21 and >75 years, used drugs of abuse, used drugs
affecting lipoprotein metabolism (statins, ﬁbrates, bile acid seques-
trants or nicotinic acid), taking drugs for treating diabetes, are on
hormone replacement therapy, had current or recent cardiovascular/
coronary heart disease, or with current or recent cancer were excluded.
Body mass index (BMI) ranged from 16.3 to 43 kg/m2 (11 underweight),
BMI <18.5 kg/m2; 210 normal/healthy body weight, BMI 18.5e
24.9 kg/m2; 113 overweight (BMI 25.0e29.9 kg/m2; 55 obese,
BMI > 30 kg/m2). The study was conducted in accordance with an
experimental protocol reviewed and approved by the UC Davis Insti-
tutional Review Board. Participants provided written informed consent.
2.1.2. Dietary sugar studies
Participants in these studies are subgroups of NIH-funded in-
vestigations involving 182 participants (DRS) [19] and 31 participants
(IPOP) [23,24]. DRS participants (92 men, 90 women) were recruited
through internet listings (craigslist.com) and local postings of ﬂyers,
underwent telephone and in-person interviews with medical history,
complete blood count, and serum biochemistry panel to assess eligi-
bility. Inclusion criteria included age 18e40 y and BMI 18e35 kg/m2
with a self-report of stable body weight during the prior 6 months.
Exclusion criteria included diabetes (fasting glucose >125 mg/dL),
evidence of renal or hepatic disease, fasting plasma triglyceride
>400 mg/dL, hypertension (>140/90 mm Hg), hemoglobin <8.5 g/
dL, and surgery for weight loss. Individuals who smoked, habitually
ingested >2 alcoholic beverages/d, exercised >3.5 h/wk at a level
more vigorous than walking, or used thyroid, lipid-lowering, glucose-
lowering, antihypertensive, antidepressant, or weight loss medications
were also excluded. The study was conducted in accordance with an
experimental protocol that was approved by the UC Davis Institutional
Review Board, and participants provided written informed consent.
Participants for IPOP were recruited through newspaper advertisements
and underwent a telephone and an in-person interview with medical
history, a complete blood count, and a serum biochemistry panel to
assess eligibility. Inclusion criteria included age from 40 to 72y and BMI
of 25e35 kg/m2 with a self-report of stable body weight during the prior
6 months. Women were considered postmenopausal based on a self-
report of no menstruation for at least 1 year. Exclusion criteria
included evidence of diabetes, renal disease, or hepatic disease; fasting
serum TG concentrations greater than 400 mg/dL; hypertension (>140/
90 mmHg); and history of surgery for weight loss. Individuals who
smoked, reported exercise of more than 3.5 h/wk at a level more
vigorous than walking, or reported having used thyroid, lipid-lowering,
glucose-lowering, antihypertensive, antidepressant, or weight-loss
medications were also excluded. Diet-related exclusion criteria
included habitual ingestion of more than 1 sugar-sweetened beverage
per day or more than 2 alcoholic beverages per day. The UC Davis
Institutional Review Board approved the experimental protocol, and
subjects provided informed consent for participation in the study.
2.1.3. CREG study
Selection criteria, interventions, and outcomes were reported previ-
ously [11,21]. The study involved sedentary, men and women with
excess weight aged 45e65y. The study was reviewed and approved
by the Institutional Review Boards (IRB) of Washington University and
Saint Louis University.
2.1.4. HERITAGE study
Plasma from 40 participants (20 males, 20 females) showing no
response (“nonresponders”) and 40 participants (20 males and 20
females) exhibiting high training-induced gains in VO2max (“re-
sponders”) were selected by ranking participants from minimal to
maximal response, stratiﬁed by sex. The current study uses baseline
data.
2.1.5. Blood chemistries and measurement of circulating
hormones
For the RRS, lipids were measured on a Hitachi 911 analyzer (Hitachi
Inc, Tokyo, Japan) at Tufts University. For the DRS and IPOP, lipid
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concentrations were measured with a Polychem Chemistry Analyzer
(PolyMedCo Inc.) with reagents from MedTest DX. Glucose concen-
trations were measured with an automated glucose analyzer (YSI) and
insulin by radioimmunoassay (Millipore).
In the CREG study, sera were analyzed in a Clinical Laboratory
Improvement Amendments (CLIA)-certiﬁed clinical laboratory for
concentrations of total, low-density lipoprotein cholesterol (LDL-C), and
high-density lipoprotein cholesterol (HDL-C), and glycerol-blanked
triglyceride concentrations using automated enzymatic/colorimetric
assays (Roche/Hitachi Modular Analytics System, Roche Diagnostics
Corporation, Indianapolis, IN). Plasma glucose was measured using the
glucose oxidase method (YSI STAT Plus; YSI Life Sciences, Yellow
Springs, OH); insulin was measured using IMMULITE Chem-
iluminescence Kits (Diagnostics Products Corporation, Los Angeles,
CA).
Very low density lipoprotein (VLDL) was calculated by subtracting
(HDL-C þ LDL-C) from total cholesterol.
Plasma adropin concentrations were determined using a commercially
available enzyme immunoassay (Peninsula Laboratories, Inc., San
Carlos, CA) previously validated and extensively used by our laboratory
[11e13,15,25]. The intra-assay coefﬁcient of variation is <5%, the
inter-assay coefﬁcient of variation is 25e30%. Plasma adropin
concentrations in the RRS and DRS were measured in singletons in
one batch. Measurements of plasma adropin in the CREG and IPOP
study samples were duplicates, as previously described [11,15]. All
samples used were EDTA-plasma collected from individuals fasted
overnight.
2.2. Regulation of Enho expression in cultured cells and mice
2.2.1. In silico analysis of the Enho promotor
RAW sequencing reads ﬁles (SRA format) downloaded from the NIH
SRA (short reads archive) server were converted to the FASTQ format
using ‘fastq-dump’ program (version 2.3.5) and aligned to the mouse
genome (mm10) using STAR (version 2.4.2a). The aligned reads were
analyzed using HOMER (version 4.8) [26]. Peaks were determined
using “ﬁndPeaks” with default parameters as FDR 0.001, fold
enrichment over input 4, Poisson p  0.0001. Motif analysis,
annotation, and quantiﬁcation of the binding sites were performed
using “ﬁndMotifsGenome.pl” or “annotatePeaks.pl”. Visualization of
ChIP-Seq signals were in IGV genome browser (version 3.0) following
fcompression of the BAM ﬁles into the TDF format.
2.2.2. Measurement of Enho gene expression in mouse liver
Rhythmicity in liver Enho expression was analyzed by qRT-PCR as
previously described [1,10,25] using total RNA previously collected
from male AKR/J mice (The Jackson Laboratories, Bar Harbor, ME)
[27]. In brief, mice were acclimated to a regular Chow diet (Purina
5015) ad libitum under a strict 12-h-light/12-h-dark cycle for 2 wk.
Staff handled the mice frequently to reduce stress of human contact.
After acclimation period, animals were killed in groups of three every
4 h over a 48-h period. Enho expression was then measured using
qRT-PCR, as previously described [1]. This experiment was reviewed
and approved by the IACUC at the Pennington Biomedical Research
Center, LSU System in Baton Rouge, LA.
The effect of dietary cholesterol on hepatic Enho expression was
investigated in three experiments. In the ﬁrst experiment, total RNA
isolated from male B6 mice fed chow or high cholesterol diet (Teklad
TD.05305) treated with diluent (control) or an RORa/g inverse agonist
(SR1001) [28] or Rev-erb agonist (SR9009) [29,30]. These
experiments were reviewed and approved by the IACUC at Saint Louis
University School of Medicine in St. Louis, MO.
The second experiment examined Enho expression in liver of six 4-wk
old mice for ﬁve of the eight founder strains of the Diversity Outbred
(DO) mouse population [31] fed a synthetic chow diet (AIN-76A,
Research Diets). After 2 wk, 3 mice from each founder strain were
switched to an atherogenic high-fat, high-cholesterol diet with cholic
acid (HFCA) diet for 16 wk, while the others remained on the synthetic
diet. Livers from each mouse were ﬂash frozen and homogenized
before RNA was extracted and used for RNA sequencing on the Illu-
mina HiSeq platform. RNA sequencing reads were aligned using
MapSplice 2 to pseudo-genomes for each founder strain. Pseudo-
genomes were built by using the coordinates of known variants that
differ between C57BL/6 and each of the other 7 strains to convert the
mm10 reference genome. RNA sequencing by maximization estima-
tion (RSEM) was used to quantify reads, and DESeq2 was used for
normalization and differential gene expression analysis.
The third experiment examined the effect of dietary cholesterol on
Enho expression in liver of mice from DO mouse population developed
from eight inbred strains of mice [31]. Full details on animal handling,
feeding, measurement of phenotypes, and microarray analysis were
previously published [32,33]. Brieﬂy, a cohort of 288 DO mice were fed
either an atherogenic high-fat, high-cholesterol diet with cholic acid
(HFCA, n ¼ 144) or a calorie-matched non-atherogenic high protein
(HP, n ¼ 144) diet for 18 wk. After diet treatment, blood was drawn to
measure lipids, including total cholesterol and HDL-C. LDL-C values
were calculated by subtracting HDL-C from total cholesterol for each
mouse. Livers from 263 mice were ﬂash frozen and homogenized
before total RNA was extracted and used for microarray analysis of
gene expression using the Affymetrix MoGene 2.1 array. For micro-
array analysis, robust multiarray average (RMA) method was used for
normalization, and probes with known SNPs from the eight founder
strains of the DO population were masked.
2.2.3. Regulation of ENHO expression in cultured HepG2 cells
HepG2 (ATCC-HB-8065) cells were maintained in advanced MEM
(Advanced MEM, Life Technologies Inc., MD) supplemented with 10%
FBS (Gemini Bio Products, CA) at 37 C in a humidiﬁed incubator under
5% CO2. Cells were seeded in 6-well plates and treated with DMSO
(SigmaeAldrich), SR9009 (10 mM) or SR1001 (10 mM) for 24 h prior to
analysis of gene expression. For these experiments, triplicates of each
conditions were done, and each experiment was repeated at least two
times, giving similar results.
The effects of cholesterol and 7-oxygenated sterols (7b-hydrox-
ysterol, 7-ketocholesterol) on ENHO expression in HepG2 cells were
examined as previously described [34] using quadruplicates. Cells
were maintained in charcoal stripped FBS (Thermo Fisher) only
(control) for 24 h, or with charcoal stripped FBS plus 10 mM
cholesterol (Sigma, C3045), 10 mM 7b-hydroxysterol (Sigma, H6891)
or 10 mM 7-ketocholesterol (Sigma, C2394). One experiment is
shown for each study; each point represents the averages for tripli-
cates or quadruplicates.
2.3. Analysis of cholesterol metabolism in transgenic mice over
expressing adropin
The impact of adropin overexpression on plasma cholesterol was
investigated in adropin transgenic (AdrTG) male and female mice on
the B6 background [1,10] fed chow or high-cholesterol diets. To
examine whether adropin may be protective against the development
of atherosclerosis, lesions in aorta of LDL receptor knock-out
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(B6.129S7-Ldlrtm1Her/J referred to hereafter as Ldlr/; purchased
from The Jackson Laboratory, Bar Harbor, ME) mice was induced by
exposing the mice to atherogenic diet for 12 wk. AdrTG mice were
crossed onto the Ldlr/ background. Male AdrTG;Ldlr/ mice
were mated with female Ldlr/ female mice producing
AdrTG;Ldlr/ and Ldlr/ mice used for these studies.
Mice were fed atherogenic diet (Teklad 88137, 42% from fat) starting
at 6 wk of age. Body weight was measured weekly. After 12 wk of
atherogenic diet, mice were euthanized, perfused with saline and
blood and aorta samples collected. Aorta were stored in 10% neutral
buffered formalin for 48 h, then transferred to ice-cold saline. Aorta
were cleaned by removing adventitious tissues, cut open, pinned and
lesions quantiﬁed using Image-Pro Plus software. Isolated plasma
fractions were sent to the Metabolic Core Facility at the The Scripps
Research Institute in Florida for analysis. Total cholesterol, triglyceride,
LDL (low density lipoproteins), HDL (high density lipoproteins), and liver
transaminases using a Cobas c311 Clinical Chemistry Analyzer (Roche
Diagnostics). Plasma lipoprotein fractions were collected by FPLC
using Bio-Rad Biologic DuoFlow System with a BioFrac Fraction Col-
lector and total cholesterol measured in each lipoprotein fractions in
96-well plates (Cholesterol E Enzymatic Kit, WAKO Pure Chemical In-
dustries) [35].
These experiments were reviewed and approved by the IACUC at Saint
Louis University School of Medicine in St. Louis, MO.
2.4. Measurement of 24-hour plasma adropin concentrations in
rhesus monkeys
Adult male rhesus monkeys were individually housed at the California
National Primate Research Center at the University of California, Davis.
The animals were fed a standard grain based primate commercial
primate diet (Lab Diets 5047, Advance Protocol Old World Primate;
30% energy as protein, 11% energy as fat, and 59% energy as car-
bohydrate) ad libitum with fresh food provided two times per day at
feeding times of 7 am and 3 pm. The monkeys were trained to present
an arm for venipuncture blood collections and samples were collected
for measurement of adropin every 2 h over a 24-hour period, during
which the animal consumed their main meals at the normally
accustomed times, although food was available for consumption at
other times. The experimental protocol was approved by the Animal
Use and Care Committee of the University of California, Davis
2.5. Statistical analysis
Data were analyzed using SPSS Statistics Version 23 (IBM). Assess-
ment of meal effects in the rhesus macaque data used a 1-way ANOVA
with repeated measures. Data was missing from 1 time point (ZT0);
analysis excluding data from that time point or estimating the missing
value using two methods (regression, group average at ZT0) did not
affect the outcome. Relationships between plasma adropin concen-
trations, demographics (sex, age, BMI, waist circumference, diastolic
and systolic blood pressure) and blood chemistries assessing car-
diometabolic risk (lipid panel, glucose, insulin and HOMA-IR) were
initially investigated using correlation (Spearman’s rho or controlling
for age, BMI). For linear regression, standardized b coefﬁcients are
reported with p values when signiﬁcance was observed. The Bonfer-
roni correction was used for post hoc analyses involving multiple
comparisons. Associations were then further explored by separating
data into quantiles ranked by plasma adropin concentration. For
comparisons of demographic and blood chemistry data between
quantiles, univariate analysis used sex and quantile as ﬁxed factors;
covariates controlling for potential confounding effects on dependent
variables were applied as needed.
3. RESULTS
3.1. Inverse association between adropin and LDL-C in men
As previously reported [11], plasma adropin concentrations exhibited a
unimodal distribution with a rightward skew and kurtosis in males and
females (concentrations in ng/ml for males; mean, 4.23; median, 3.11;
std. deviation, 3.91; skewness, 3.12; kurtosis, 11.94; for females,
mean, 3.25; median, 2.72; std. deviation, 2.66; skewness, 4.45;
kurtosis, 29.68, effect of sex, p < 0.001) (Figure 1A). Correlation
analysis using log-transformed data identiﬁed an inverse association
between plasma adropin concentration and HOMA-IR (Spearman’s
rho ¼ 0.077, p < 0.05), BPsys (rho ¼ 0.072, p < 0.05), and
indices of cholesterol metabolism: total cholesterol (rho ¼ 0.118,
p ¼ 0.001), LDL-C (rho ¼ 0.123, p ¼ 0.001), non-HDL-C
(rho ¼ 0.099, p < 0.01). However, when adjusted for BMI and
age, the only correlations observed were with indices of cholesterol
metabolism (total cholesterol, r ¼ 0.188, p ¼ 0.001; LDL-C,
r ¼ 0.194, p ¼ 0.001; nonHDL-C, r ¼ 0.177, p ¼ 0.001). We
therefore focused on examining relationships between adropin and
cholesterol metabolism.
The relationship between plasma adropin concentrations and choles-
terol is sex-dependent, and is only observed in males (Figure 1B and
C). Limiting the correlation analysis to men increased correlation co-
efﬁcients (total cholesterol, rho ¼ 0.246, p ¼ 0.001; LDL-C
(rho ¼ 0.224, p < 0.001) and non-HDL-C (rho ¼ 0.213,
p< 0.001). These correlations remained signiﬁcant when adjusted for
age and BMI (total cholesterol, r ¼ 0.171, p < 0.005; LDL-C,
r ¼ 0.1794, p < 0.001; non-HDL-C, r ¼ 0.177, p ¼ 0.001).
Separating the data into quartiles ranked low to high by LDL-C levels
revealed the predicted decline in plasma adropin concentrations with
increasing LDL-C in men, but not women (Figure 1D).
Obesity is a risk factor for coronary heart disease, at least in part due to
increased LDL-C [36]. To determine whether plasma adropin con-
centrations interact with obesity to determine LDL-C levels in men,
data were separated into tertiles ranked by either BMI. Each tertile
(n ¼ 116) was then separated into quartiles ranked by plasma adropin
concentration (n ¼ 29). Plasma adropin data shown in Table 1
demonstrate the skewed distribution; plasma adropin concentrations
were markedly higher in the 4th adropin quartile owing to the cluster of
men with extreme values (Figure 1A).
The cholesterol data shown in Figure 2 were analyzed using age and
BMI as covariates, as both variables exhibited the well-known positive
effect on cholesterol levels (data not shown). There was a signiﬁcant
effect of adropin quartile on LDL-C, nonHDL-C and total cholesterol
(p < 0.005), but not for HDL-C (Figure 2A,C, E, G); average concen-
trations of LDL-C, nonHDL-C and total cholesterol were signiﬁcantly
lower in the 3rd and 4th quartile relative to 1st quartile.
Analysis of the deviation from the mean for cholesterol suggests that
the effects of BMI tertiling and adropin quartiling are not equal for LDL-
C, nonHDL-C and total cholesterol (Figure 2B,D, F). In general terms,
plasma cholesterol levels adjusted for age and BMI appeared to be
highest in overweight men with low adropin, and lowest in overweight
men with higher plasma adropin concentrations. This difference is not
evident for HDL-C (Figure 2H).
Indices of insulin sensitivity adjusted for BMI, ethnicity, age, and study,
of men and women grouped into quartiles ranked by plasma adropin
concentration were not signiﬁcantly different between adropin quartile
(Table 1). Differences in BMI and blood pressure were also not
observed between adropin quartile (supplemental data, Table S2).
Differences in average age between BMI tertile were also consistent
with the known association between aging and weight gain (age in
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years for BMI 1st tertile, 33.3  1.46; 2nd tertile, 37.6  1.45; 3rd
tertile, 44.2  1.36; effect of BMI tertile, p < 0.001). Males in the BMI
3rd tertile were signiﬁcantly older relative to the 1st and 2nd tertiles
(p < 0.005). Surprisingly, while observing an inverse association
between age and plasma adropin concentrations, the average age of
the adropin quartiles was not signiﬁcantly different (data not shown).
However, there was a signiﬁcant interaction between BMI tertile and
age quartile (BMI tertile  adropin quartile interaction, p ¼ 0.001).
To further examine the relationship between plasma adropin con-
centration, aging and obesity we repeated the analysis separating the
data into tertiles ranked by age, and then quartiling ranked by plasma
adropin concentration. Aging-related increases in BMI are evident in all
men (effect of age tertile, p < 0.001) (Figure 3A,B). However, high
plasma adropin concentrations appears to associate with a phenotype
characterized by leanness early in youth, but increased risk of obesity
in the mid-to late-stages of life (Figure 3C,D) (age tertile  adropin
quartile interaction, p < 0.05).
3.2. Regulation of adropin expression by cholesterol, Rev-Erb and
RORa/g
Adropin expression and circulating levels appear to be nutritionally
regulated in mice and humans [1,10e13,25,37,38]. The current
study suggests an important link between adropin and cholesterol
metabolism. However, the mechanisms that associate metabolic
control with adropin expression are unclear. Measurement of Enho
expression in liver collected at 4 h intervals over 48 h from male AKR/
J mice fed ad libitum shows rhythmicity (Figure 4A). Enho expression
peaks between ZT20-ZT4 (4 h before and after lights-on at 06:00 h),
coincident with the last phase of peak nutrient consumption in
nocturnal mice.
Plasma adropin concentrations in humans relate to macronutrient
composition of the diet [11,13]. However, evidence for rapid meal-
related responses is less clear, perhaps due to heterogeneity be-
tween individuals [11,13,15]. In nonhuman primates (male rhesus
macaques, n ¼ 6) maintained on a standard low-fat chow diet, evi-
dence for a rhythm in plasma adropin concentrations in samples
collected at 2 h interval is observed (effect of time, p < 0.05), with
peaks centered around the timing of food presentation (Figure 4BeD).
Peak Enho expression in mouse liver coincides with maximal lipid
production driven by the nuclear receptor RORa/g [39]. Inspection of
the ENHO gene sequence revealed a multitude of potential upstream
transcription factor binding sites including members of the Sp family
(Sp1, Sp2 and Sp5), estrogen-related receptors alpha and beta (Erra,
Esrrb), several members of the Homeobox A family involved in
Figure 1: Inverse association between plasma adropin concentrations LDL-C levels in data pooled from the RRS, CREG, DRS, IPOP and HERITAGE studies. (A) Box and
whisker plot showing distribution and range of plasma adropin concentrations in males and females. Extreme values are shown as circles. Relationship between fasting plasma
adropin concentration and LDL-C (Log2-transformed) in males (B) and females (C). In panels B and C shading is used to indicate separation of data into quartiles ranked by plasma
adropin concentration. (D) Plasma adropin concentrations in data pooled into quartiles by ranking LDL-C levels low to high (1st through 4th quartile read left to right in the panel).
Mean plasma adropin concentrations decline with increasing LDLc in men, but not woman. LDL-C levels in D are estimated marginal means  SEM adjusted for age and BMI. a
p < 0.01 vs. the 4th LDL-C quartile for males, p < 0.05 vs. females all quartiles; b p < 0.05 vs. females in the 1st quartile.
Table 1 e Plasma adropin concentrations and indices of insulin sensitivity in pooled data grouped by sex and adropin quartile. Laboratory
measurements are adjusted for age and BMI. N is shown in parenthesis.
Demographic, laboratory
measurement
Sex Group averages by sex Group averages by sex, adropin quartile
1st 2nd 3rd 4th
Blood chemistries
Adropin (ng/ml) M 4.26  0.13 (348) 1.43  0.27 (87) 2.72  0.27 (87) 3.75  0.27 (87) 9.24  0.27 (87)
F 3.24  0.13 (400) 1.31  0.25 (100) 2.31  0.25 (100) 3.27  0.25 (100) 6.07  0.25 (100)
Statistics Sex, p < 0.000 Quartile, p < 0.000.; Interaction, p < 0.000
Insulin (mU/ml) M 12.80  0.30 (347) 13.19  0.59 (87) 12.00  0.59 (87) 12.76  0.60 (86) 13.25  0.59 (87)
F 13.01  0.28 (390) 13.36  0.55 (99) 13.04  0.55 (98) 12.75  0.56 (97) 12.88  0.56 (96)
Glucose (mg/dL) M 92.7  0.4 (348) 93.7  0.9 (87) 91.7  0.9 (87) 92.9  0.9 (85) 92.3  0.9 (87)
F 90.8  0.4 (398) 90.7  0.8 (100) 91.3  0.8 (99) 90.8  0.8 (99) 90.3  0.8 (100)
Statistics Sex, p < 0.01
HOMA-IR M 2.96  0.08 (346) 3.07  0.16 (87) 2.74  0.16 (87) 2.96  0.16 (86) 3.09  0.16 (86)
F 2.98  0.08 (388) 3.02  0.15 (99) 3.02  0.15 (97) 2.96  0.15 (96) 2.91  0.15 (96)
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Figure 2: Signiﬁcantly lower age- and BMI-adjusted levels of atherogenic cholesterol in men with high plasma adropin concentrations. Men were separated into tertiles
(n ¼ 116) ranked by BMI (low to high), and then further ranked within BMI tertile into quartiles ranked by plasma adropin concentration. Average concentrations of LDL-C (A),
nonHDL-C (C), total cholesterol (E) and HDL-C (G) within adropin quartile (n ¼ 87/group). Relative difference (plus or minus) to the mean of all samples for LDL-C (B), nonHDL-C (D),
total cholesterol (F) and HDL-C (H) are shown within groups deﬁned by BMI tertile and adropin quartile (n ¼ 29). *p< 0.05 vs. adropin 1st quartile or groups indicated by line;
**p < 0.01 vs. adropin 1st quartile or groups indicated by line. Values are estimated marginal means  SEM.
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embryonic development, Nr4a1 (Nur77), Srebf1a, Bmal1, members of
the Krueppel-like factor (KLF) family, thyroid hormone receptor (THRb)
and vitamin D receptor (VDR) (data not shown).
The Srebf1 binding site is of interest, given its role in regulating
lipogenesis [40]. However, hepatic adropin expression in liver is
suppressed by high sugar diets compared to low-fat, low-sugar chow
diets [11]. Hepatic adropin expression is also rapidly stimulated by
high-fat diets [1,25]. Finally, hepatic adropin expression is suppressed
in mouse models of obesity in which hepatic lipogenesis is increased
by the insulin-Srebpf1 pathway [1,41,42]. These observations are not
consistent with a major direct role for adropin in hepatic lipogenesis.
ROR and Rev-erb on the other hand drive rhythms in the expression of
genes involved in lipid and carbohydrate metabolism [39,43]. Analysis
of ROR, Rev-Erb, H3K9ac ChIP-Seq and GRO-Seq results derived from
liver [39] indicated two overlapping RORa/g and Rev-Erb binding sites
upstream (339 bp) and down-stream (þ2952 bp) of the Enho
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Figure 3: An interaction between age and adropin quartile on BMI in men. Men were separated into tertiles (n ¼ 116) ranked by age (youngest to oldest), and then further
ranked within age tertile into quartiles ranked by plasma adropin concentration. (A) Average age in years within each age tertile. (B) Average BMI within age tertile demonstrating
the predicted increase observed with aging. * all groups are signiﬁcantly different, 2nd vs 3rd tertile, p < 0.05; p < 0.005 for other comparisons. (C) Average BMI within adropin
quartile (n ¼ 87). (D) Average difference from the mean for BMI within groups deﬁned by BMI tertile and adropin quartile (n ¼ 29). The interaction between age tertile and adropin
quartile is signiﬁcant (p < 0.05). Men in the youngest age tertile generally have a lower BMI compared to the mean for all participants. Conversely, men in the oldest age tertile
generally have a higher BMI. The largest difference in BMI between age tertile observed in men with higher plasma adropin concentrations. On the other hand, gains in BMI
between age groups is modest in men with low plasma adropin concentrations.
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transcription start site (Figure 5A). Comparison of GRO-Seq signals at
ZT10 and ZT22 indicate Enho is transcriptionally repressed at ZT10, a
time point when Rev-Erb is highly expressed. Enho transcription is
activated at ZT22, when Rev-Erb is not expressed. Importantly, these
dynamic, time-dependent repression and activation events correlated
with similar changes in H3K9 acetylation at the Enho gene locus. As a
nuclear receptor responsive to cholesterol and oxysterols [39,43], ROR
could provide a link between cholesterol metabolism with Enho
expression in the liver. These results also suggest an ability of Rev-erb
to dominantly repress Enho gene transcription. ROR may play a pos-
itive role, given its ability to bind to overlapping Rev-Erb sites and the
reported constitutive activation function of ROR.
The potential role of cholesterol in regulating Enho expression was then
investigated in male B6 mice fed chow or high cholesterol diet (Teklad
TD.05305); some of these mice were also treated with an RORa/g
inverse agonist (SR1001) [28] or Rev-erb agonist (SR9009) [29,30]. If
RORa/g activates Enho transcription; an inverse agonist would be
hypothesized to suppress expression. Agonists enhancing Rev-erb
repressor activity would also suppress expression. Twice-daily in-
jections of 100 mg/kg ip. of the Rev-erb agonist SR9009 for 10 days
[29] reduced liver Enho expression by 70%; however treatment with
RORa/g inverse agonist SR1001 had no effect (Figure 5B). Feeding
male B6 mice a high cholesterol diet for 31 d suppressed hepatic Enho
expression (Figure 5B); SR9009 treatment for 21 d did not affect Enho
expression, while SR1001 treatment resulted in further suppression of
expression (Figure 5B).
We then examined liver Enho expression in 5 inbred strains (A/J,
WSBEiJ, B6, 129S1 and NODShiLtJ) used for the Diversity Outbred
(DO) population [31]. In all strains maintained on the high cholesterol
diet, hepatic Enho expression was reduced by 1.3e4.8-fold compared
to controls (Figure 5C). In the mixed background DO population, Enho
expression in liver was reduced by 1.5-fold in mice maintained on
HFCA diet related to controls (RMA values for controls fed a non-
atherogenic high protein diet, mean, 5.34; SD, 0.52; n ¼ 139; for
HFCA-fed mice, mean, 4.78, SD, 0.64, n ¼ 123; p < 0.000).
The lack of response to SR1001 in chow-fed mice, and of SR9009 in
mice fed the cholesterol diet, may reﬂect ceiling/ﬂoor effects on Enho
expression in the liver and/or result from indirect metabolic conse-
quences of chronic treatment. To more directly examine regulation of
ENHO expression, HepG2 cells were treated with SR1001 or SR9009.
The Rev-erb agonist SR9009 reduced ENHO expression by 50% in
HepG2 cells (Figure 5D), while the ROR inverse agonist SR1001 also
suppressed Enho expression (Figure 5E). The 7-oxygenated sterols 7-
b-hydroxysterol (7b-OHC) and 7-ketocholesterol (7-KC) are high af-
ﬁnity ligands for RORa, and are thought to function as RORa/g inverse
agonists [34]. In HepG2 cells maintained in charcoal-treated FBS to
reduce lipids, coincubation with 7b-OHC and 7-KC for 24 h markedly
suppressed ENHO expression, along with genes involved in cholesterol
and fatty acid metabolism (Figure 5F).
3.3. Adropin does not reduce cholesterol levels or prevent
atherosclerosis in mice
We next examined responses of transgenic mice over expressing
adropin controlled by a human bactin promotor (AdrTG) [1,10] to
high cholesterol diets (HCD). Weight gain, atherosclerosis and hyper-
cholesterolemia observed in AdrTG;Ldlr/ mice fed a HCD for 12 wk
was similar to that observed in Ldlr/ mice (Figure 6AeC). Total
cholesterol levels in chow-fed AdrTG;Ldlr/ and Ldlr/ mice was
not signiﬁcantly different (Figure 6D). Analysis of liver gene expression
indicated a signiﬁcant increase in Enho in the AdrTG (Figure 7).
Expression of some enzymes involved in cholesterol biosynthesis were
Figure 4: Rhythmicity in hepatic Enho expression in mice (A) and in plasma
adropin concentration in nonhuman primates (BeE). (A) Liver Enho expression at
4 h intervals over 48 h in AKR/J mice (n ¼ 3/group). Peak expression occurs between
ZT20 and ZT4, corresponding to a window 4 h prior to and after lights on at 06:00 h.
(B) Averaged plasma adropin concentrations (n ¼ 6/group). (C) Averaged deviation from
the 24 h mean. (D) Plasma adropin concentration data shown for the individual
monkeys. *, p < 0.05 vs. 12:00 h and 24:00 h; **, p < 0.05 vs. 06:00 h, 12:00 h and
24:00 h. Data shown in panels B-D are double plotted.
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Figure 5: Rhythms in adropin expression are regulated by the interaction of RORa/g and Rev-erb with binding sites upstream of the Enho gene; dietary cholesterol suppresses
hepatic Enho expression. (A) An analysis of transcriptional activity of the mouse Enho gene in liver at ZT10 and ZT22 using ChIP-Seq and Gro-SEQ. Histone acetylation is also
shown. (B) Liver Enho expression in male B6 mice fed chow (n ¼ 6 for vehicle and SR9009, n ¼ 5 for SR1001) or high cholesterol diet treated with the RORa/g inverse agonist
SR9009 or Rev-erb agonist SR1001 (n ¼ 9/group). *, p < 0.05; ***, p < 0.000. (C) Liver Enho expression in livers of 5 inbred strains used for the Diversity Outbred population
maintained on HFCA or control diet (n ¼ 3/group). ENHO expression in HepG2 cells treated with a Rev-erb agonist (D) or RORa/g inverse agonist (E). (F) Suppression of ENHO
expression in HepG2 cells cultured in reduced lipid serum treated with 10 mM 7-beta-hydoxysterol (7b-OHC), 7-Ketocholesterol (7-KC) and cholesterol for 24 h. With the exception
of HMGCR, treatment had a signiﬁcant effect on gene expression (p < 0.005). Columns marked a are signiﬁcantly different from control, p < 0.005; b from cholesterol (p < 0.05);
c the values between all groups were signiﬁcantly different (p < 0.05 control vs. cholesterol; p < 0.001 for the other groups); d from cholesterol (p < 0.01); e from control
(p < 0.05 for cholesterol, p < 0.001 for 7b-OHC and 7-KC).
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Figure 6: Adropin overexpression does not reduce cholesterol levels or prevent atherosclerosis in mice. (A) Body weight data for male and female Ldlr/ or
AdrTG;Ldlr/ mice. (B) Atherosclerotic lesions in Ldlr/ and AdrTG;Ldlr/ mice maintained on a high cholesterol (HC) diet are similar. (C) Measurements of plasma
cholesterol (total, HDL, LDL) are similar in Ldlr/ and AdrTG;Ldlr/ mice maintained on a high cholesterol (HC) diet are similar. (D) Total cholesterol levels and the distribution
of cholesterol between VLDL, IDL/LDL and HDL fractions are similar in chow-fed Ldlr/ and AdrTG;Ldlr/ mice.
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suppressed in mice carrying the adropin transgene, irrespective of Ldlr
genotype. However, expression of HMG-coA Reductase (Hmgcr) which
is the rate controlling enzyme of the mevalonate pathway producing
cholesterol, was normal in AdrTG (Figure 7).
4. DISCUSSION
The current study began as an extension of previous investigations of
associations between plasma adropin concentrations and indices of
obesity and metabolic control in humans [11e13,15]. Earlier studies
using relatively small samples observed associations between plasma
adropin concentrations and sex [11,15], obesity [15], age [15], and
indices insulin resistance and dyslipidema [11]. The current study
suggests that, in a larger sample with less deﬁned inclusion criteria,
sex and cholesterol levels are major determinants of plasma adropin
concentrations.
The current study also suggests a relationship between plasma
adropin concentrations and indices of obesity that is more complex
than previously reported. In young men, high plasma adropin con-
centrations are associated with a lean phenotype. By the mid-30’s and
later in life, this association is lost and may in fact be reversed. Given
that adropin associates with increased relative saturated fat intake
[11,13] and suppresses fat oxidation [2,10], weight instability over
time might be a predicted outcome. However, this hypothesis is not
supported by the lean phenotype observed in male B6 transgenic mice
over expressing adropin. Prospective studies examining the relation-
ship between aging, weight gain and plasma adropin concentrations
are clearly needed, both in humans and in laboratory models. In
addition, new studies in nonhuman primate models with controlled
feeding paradigms, liver biopsies, and importantly investigation of the
metabolic/endocrine effects of exogenous adropin administration that
cannot be performed in humans are likely to help clarify the physio-
logical role of adropin in intermediary metabolism.
4.1. Plasma adropin concentrations may provide a biomarker for
risk of atherogenic hypercholesterolemia in obesity
The current experiments identify a relationship between plasma
adropin concentrations and indices of atherogenic hypercholesterole-
mia that appears limited to men, indicating a major sex-difference in
relationship between adropin and cholesterol homeostasis. Moreover,
the relationship appears to be most pronounced in overweight to obese
participants, suggesting an interaction between plasma adropin con-
centrations and obesity in determining LDL-C levels. There was
however no association between plasma adropin concentrations and
VLDL-C or HDL-C. Plasma adropin concentrations may thus associate
with differences in the equilibrium between cholesterol synthesis and
processing of circulating lipoprotein particles.
Experiments using mice over expressing adropin do not support a
signiﬁcant role for adropin in regulating cholesterol uptake from the
diet, clearance from the circulation or cholesterol biosynthesis. Rather,
these data suggest a relationship heavily biased towards suppression
of adropin synthesis by cholesterol. Evidence for suppression of the
expression of several genes involved in cholesterol synthesis was
evident in the liver of AdrTG. While suggesting the possibility of a role in
regulating cholesterol biosynthesis, Hmgcr expression which is rate-
limiting in cholesterol biosynthesis is normal in AdrTG. Any changes
in gene expression also appear to be insufﬁcient to reduce circulating
cholesterol levels. The current results are not comprehensive, and
cannot rule out a role for adropin in regulating cholesterol biosynthesis.
However, the potential impact appears minor and does not signiﬁcantly
impact hypercholesterolemia induced by diet and/or Ldlr-deﬁciency in
mice.
Cholesterol biosynthesis is regulated through a sterol-sensing mech-
anism involving sterol regulatory element binding protein 2 (Srepb2)
[44]. Srebp2 is a transcriptional activator that controls expression of
enzymes involved in cholesterol biosynthesis. Inhibition of Srebp2
activity by oxygenated derivatives of cholesterol is a feedback mech-
anism linking cholesterol biosynthesis with demand. In mice, dietary
cholesterol also suppresses Enho expression. Participation of adropin
in a simple feedback mechanism where cholesterol regulates adropin
expression and its own synthesis in parallel, while attractive, may not
explain the observed association. For example, increased endogenous
cholesterol production is a major factor contributing to hypercholes-
terolemia in obesity. Plasma adropin concentrations also appear to be
lower in situations of obesity-related hypercholesterolemia, a condition
in which cholesterol synthesis is likely increased.
The relationship between plasma adropin concentrations and athero-
genic cholesterol levels may not be causal in nature. Rather, circulating
adropin may provide an indirect biomarker of a metabolic phenotype
that predisposes men to changes in LDL-C. Suppression of adropin by
cholesterol may however be relevant to risk of vascular disease. Low
adropin has been associated with vascular dysfunction, at least
partially through effects on endothelial nitic oxide synthase activity
[5,6,45,46].
It is important to note some of the deﬁciencies in the current study that
limit our ability to draw conclusions. Rodents lack cholesterol ester
transfer protein (CETP), which is involved in the heteroexchange of
cholesterol esters and TG between HDL and VLDL [47]. It is also not
clear that plasma adropin concentrations in humans or mice are he-
patic in origin.
4.2. Adropin expression is regulated by the core elements of the
biological clock
Adropin was originally identiﬁed as a secreted factor signaling meta-
bolic conditions that are responsive to dietary macronutrients and
energy balance [1]. The initial studies in male B6 mice suggest that
energy sufﬁciency is a requirement for adropin expression in liver [1].
The degree to which feeding stimulates adropin expression is inﬂu-
enced by dietary macronutrients; high fat diets have a more pro-
nounced stimulatory effect on expression, while diets rich in simple
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Figure 7: Adropin overexpression does not suppress 3-Hydroxy-3-
Methylglutaryl-CoA Reductase (Hmgcr) expression in the mouse liver. Expres-
sion of the adropin transcript is signiﬁcantly increased in mice expressing the adropin
transgene (AdrTG). While some genes exhibit a modest reduction in expression, the
expression of HMGCR which is rate limiting for cholesterol synthesis is normal. The
data shown are estimated marginal means of genes measured using qRT-PCR.
*p < 0.05 compared to mice not expressing the adropin transgene. LSS: lanosterol
synthase, catalyzes the ﬁrst step in the biosynthesis of cholesterol. MVK: mevalonate
kinase, catalyzes the second step in the biosynthesis of cholesterol. SC4MOL, a sterol-
C4-methyl oxidase that is localized to the endoplasmic reticulum membrane thought to
function in cholesterol synthesis.
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sugars are less effective during re-feeding and may be inhibitory when
compared to chow-fed conditions [1,11,25].
In the current study, peak adropin expression in the mouse associates
with activation of transcription by ROR, while the nadir involves the
transcriptional Rev-erb. In human HepG2 cells, small molecules
affecting the repressor activity of Rev-erb and transcriptional activation
by RORa/g rapidly changed ENHO expression. Interestingly, high fat
diets which increase hepatic adropin expression [1] have also been
reported to increase RORa expression in the liver [48]. The involve-
ment of these nuclear receptors also provides plausible nutrient
sensing mechanisms in the regulation of adropin expression. The
ligand-binding domain of ROR binds to cholesterol, oxysterols and fatty
acid [43]. Oxygenated sterols have an inhibitory effect of transcriptional
activity of RORa and RORg in cell-based assays, functioning as inverse
agonists [34]. Cholesterol, 7b-hydroxycholesterol and 7-
ketocholesterol suppressed ENHO expression in cultured HepG2
cells. In mice, suppression of liver Enho expression by exogenous
(dietary) cholesterol was evident in a genetically-diverse population,
and is not strain-dependent.
Adropin may function as a secreted output of the biological clock that
coordinate rhythms in metabolism with circadian time and metabolic
condition. The exact physiological role of adropin in the liver is un-
known. However, adropin has been shown to regulate fuel selection in
skeletal muscle to reduce fat oxidation while enhancing glucose
oxidation [2,10].
The relationship between plasma adropin concentrations, diet and
meal time is less clear in humans [11e13]. In the current study, a
nonhuman primate model (rhesus macaques) was used to examine
whether plasma adropin concentrations exhibit a diurnal pattern that
may be inﬂuenced by feeding. Evidence for two peaks during the
daytime were observed, with a clear decline during the resting
nighttime phase when the animals are not eating. This suggests that
circulating adropin levels are labile in responding to nutrient intake. As
an experimental model, rhesus monkeys have clear advantages when
compared with both mice and humans. In terms of evolution and body
size, the outbred rhesus monkeys maintained in primate colonies are
more relevant to human physiology than inbred mouse strains.
Compared to humans, experiments using rhesus are more controlled in
terms of dietary history, ethnicity and health background.
5. CONCLUSIONS
The outcomes from these experiments suggest that adropin is an
output of the biological clock. Peak adropin synthesis and presumably
activity in the liver correlate with periods of maximal nutrient pro-
cessing and lipid production. While adropin appears to prevent stea-
tosis in male B6 mice fed high fat diets [1,25], the exact functional
relationship between adropin and hepatic carbohydrate lipid meta-
bolism requires further investigation. Further studies examining
whether adropin expression in non-hepatic tissues exhibits rhythmicity
are also required. Plasma adropin concentrations may provide a useful
biomarker for identifying men at risk for elevated LDL-C with obesity.
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